Work

Oral Administration of Mavorixafor, a CXCR4 Antagonist, Increases Peripheral White Blood Cell Counts across Different Disease States

Year: 2021

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2021-152990

Authors: David C. Dale, Steven P. Treon, David F. McDermott, Diego Cadavid, Xia Luo, Varun Garg, Weihua Tang, Honghua Jiang, Kelly Chen, Arthur G. Taveras, Ashish Bhandari, Jean Donadieu

Institutions: University of Washington, Harvard University, Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, X4 Pharmaceuticals, Inc. (United States), Sorbonne Université, Hôpital Armand-Trousseau, Assistance Publique – Hôpitaux de Paris

Language: English

Topic: Chemokine receptors and signaling

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3214561011

Cites:

Cited by: 4

Related to: 10